Protease Inhibitor Resistance Is Uncommon in HIV-1 Subtype C Infected Patients on Failing Second-Line Lopinavir/r-Containing Antiretroviral Therapy in South Africa

<table>Comparison of changes from HXB2 reference between 45 lopinavir/r-exposed (light gray bars) versus 226 LPV-naïve patients (dark gray bars). Only L63P was significantly more frequent in lopinavir/r-exposed than -naïve patients (<svg height="11.1" id="M12" style="vertical-align:-0.17555pt" version="1.1" viewbox="0 0 63.962502 11.1" width="63.962502" xmlns="http://www.w3.org/2000/svg">
<g transform="matrix(1.25,0,0,-1.25,0,11.1)">
<g transform="translate(72,-63.12)">
<text transform="matrix(1,0,0,-1,-71.95,63.35)">
<tspan style="font-size: 12.50px; " x="0" y="0">𝑃</tspan>
<tspan style="font-size: 12.50px; " x="10.890113" y="0">=</tspan>
<tspan style="font-size: 12.50px; " x="22.930502" y="0">.</tspan>
<tspan style="font-size: 12.50px; " x="26.056252" y="0">0</tspan>
<tspan style="font-size: 12.50px; " x="32.307751" y="0">4</tspan>
<tspan style="font-size: 12.50px; " x="38.559254" y="0">3</tspan>
<tspan style="font-size: 12.50px; " x="44.810753" y="0">5</tspan>
</text>
</g>
</g>
</svg>).</table>

AIDS Research and Treatment

fig1

Figure 1

Figure 1: Protease Inhibitor Resistance Is Uncommon in HIV-1 Subtype C Infected Patients on Failing Second-Line Lopinavir/r-Containing Antiretroviral Therapy in South Africa 

Figure 1 | Protease Inhibitor Resistance Is Uncommon in HIV-1 Subtype C Infected Patients on Failing Second-Line Lopinavir/r-Containing Antiretroviral Therapy in South Africa 